MX2015005732A - Compuestos tricíclicos y métodos para hacer y utilizar los mismos. - Google Patents

Compuestos tricíclicos y métodos para hacer y utilizar los mismos.

Info

Publication number
MX2015005732A
MX2015005732A MX2015005732A MX2015005732A MX2015005732A MX 2015005732 A MX2015005732 A MX 2015005732A MX 2015005732 A MX2015005732 A MX 2015005732A MX 2015005732 A MX2015005732 A MX 2015005732A MX 2015005732 A MX2015005732 A MX 2015005732A
Authority
MX
Mexico
Prior art keywords
methods
tricyclic compounds
making
same
compounds
Prior art date
Application number
MX2015005732A
Other languages
English (en)
Inventor
Robert Zahler
Thomas David Pallin
Susan Mary Cramp
Original Assignee
Zafgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zafgen Inc filed Critical Zafgen Inc
Publication of MX2015005732A publication Critical patent/MX2015005732A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La invención proporciona compuestos tricíclicos y su uso en el tratamiento de trastornos médicos, como la obesidad; se proporcionan composiciones farmacéuticas y métodos para elaborar varios compuestos tricíclicos; se contempla que los compuestos tienen actividad contra la metionil aminopeptidasa 2.
MX2015005732A 2012-11-05 2013-11-05 Compuestos tricíclicos y métodos para hacer y utilizar los mismos. MX2015005732A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261722455P 2012-11-05 2012-11-05
PCT/US2013/068473 WO2014071363A1 (en) 2012-11-05 2013-11-05 Tricyclic compounds and methods of making and using same

Publications (1)

Publication Number Publication Date
MX2015005732A true MX2015005732A (es) 2015-12-16

Family

ID=49681126

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005732A MX2015005732A (es) 2012-11-05 2013-11-05 Compuestos tricíclicos y métodos para hacer y utilizar los mismos.

Country Status (10)

Country Link
US (1) US10174009B2 (es)
EP (1) EP2917197B1 (es)
JP (1) JP2015536981A (es)
KR (1) KR20150079952A (es)
CN (1) CN104870433A (es)
AU (1) AU2013337282A1 (es)
BR (1) BR112015010225A2 (es)
CA (1) CA2890342A1 (es)
MX (1) MX2015005732A (es)
WO (1) WO2014071363A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012253757B2 (en) 2011-05-06 2017-04-13 Zafgen Inc. Partially saturated tricyclic compounds and methods of making and using same
CA2861381A1 (en) 2012-01-18 2013-07-25 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
US10174009B2 (en) 2012-11-05 2019-01-08 Zafgen, Inc. Tricyclic sulphonamide compounds and methods of making and using same
BR112015010196A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc métodos de tratar doença do fígado
KR20150080614A (ko) 2012-11-05 2015-07-09 자프겐 인크. 비만의 치료 및/또는 제어에서 사용하기 위한 트리시클릭 화합물
CN109796452B (zh) * 2019-02-28 2021-08-06 郑州大学 环戊二烯并二氢喹啉类化合物及其制备方法
WO2021105115A1 (en) 2019-11-28 2021-06-03 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164410A (en) 1988-01-09 1992-11-17 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
PH26256A (en) 1988-08-12 1992-04-01 Fujisawa Pharmaceutical Co Oxaspiro [2,5] octane derivative
US5166172A (en) 1988-09-01 1992-11-24 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
US5180738A (en) 1988-09-01 1993-01-19 Takeda Chemical Industries Fumagillol derivatives and pharmaceutical compositions thereof
KR0138530B1 (ko) 1988-09-01 1998-05-15 우메모또 요시마사 푸마길롤 유도체
US5288722A (en) 1989-03-06 1994-02-22 Takeda Chemical Industries, Ltd. 6-amino-6-desoxyfumagillols, production and use thereof
ATE87623T1 (de) 1989-03-06 1993-04-15 Takeda Chemical Industries Ltd 6-epifumagillole, ihre herstellung und ihre verwendung.
US6017954A (en) 1989-08-10 2000-01-25 Children's Medical Center Corp. Method of treating tumors using O-substituted fumagillol derivatives
US5290807A (en) 1989-08-10 1994-03-01 Children's Medical Center Corporation Method for regressing angiogenesis using o-substituted fumagillol derivatives
EP0415294A3 (en) 1989-08-31 1991-06-12 Takeda Chemical Industries, Ltd. Cyclohexanol derivatives, production and use thereof
TW282399B (es) 1990-05-25 1996-08-01 Takeda Pharm Industry Co Ltd
US5238950A (en) 1991-12-17 1993-08-24 Schering Corporation Inhibitors of platelet-derived growth factor
DE69330690T2 (de) 1992-01-30 2002-06-20 Takeda Chemical Industries Ltd Verfahren zur Herstellung hoch-wasserlöslicher Zyklodextrinkomplexe
ATE153854T1 (de) 1992-12-16 1997-06-15 Takeda Chemical Industries Ltd Stabile pharmazeutische zubereitung mit fumagillolderivaten
JP3260378B2 (ja) 1995-03-27 2002-02-25 サノフィーサンテラボ 腸感染に対する薬物の調製のためのフマギロールおよびその誘導体の使用
CA2234401A1 (en) 1995-10-11 1997-04-17 Fujisawa Pharmaceutical Co., Ltd. Vascular permeation inhibitor
EP0799616A1 (en) 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
AU3968597A (en) 1996-08-02 1998-02-25 Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors
US6281245B1 (en) 1996-10-28 2001-08-28 Versicor, Inc. Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
US7115632B1 (en) 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
CA2283272A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
US6207704B1 (en) 1997-06-09 2001-03-27 Massachusetts Institute Of Technology Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof
ES2224465T3 (es) 1997-10-31 2005-03-01 Children's Medical Center Corporation Metodo para regular el tamaño y el crecimiento del tejido normal vascularizado.
DE69827664T2 (de) 1997-12-23 2005-12-08 Warner-Lambert Co. Llc Thioharnstoffverbindungen, zusammensetzungen sowie verfahren zur behandlung oder verhütung von entzündlichen erkrankungen und atherosklerose
US6242494B1 (en) 1998-05-01 2001-06-05 Abbott Laboratories Substituted β-amino acid inhibitors of methionine aminopeptidase-2
KR100357542B1 (ko) 1998-05-15 2002-10-18 주식회사종근당 푸마질롤 유도체 및 그 제조방법
KR100357541B1 (ko) 1998-05-15 2002-10-18 주식회사종근당 5-데메톡시 푸마질롤 유도체 및 그 제조방법
JP2000116337A (ja) 1998-10-09 2000-04-25 Nippon Shokuhin Kako Co Ltd ペットフード
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
DE60027420T2 (de) 1999-04-28 2006-11-16 Aventis Pharma Deutschland Gmbh Tri-aryl-säurederivate als ppar rezeptor liganden
AU7989400A (en) 1999-10-01 2001-05-10 Smithkline Beecham Corporation Compounds and methods
US20020002152A1 (en) 2000-04-14 2002-01-03 Craig Richard A. Hydrazide and alkoxyamide angiogenesis inhibitors
US6323228B1 (en) 2000-09-15 2001-11-27 Abbott Laboratories 3-substituted indole angiogenesis inhibitors
AR030631A1 (es) 2000-09-29 2003-08-27 Abbott Lab Polipeptidos antiangiogenicos y metodos para inhibir la angiogenesis
EP1330447A2 (en) 2000-11-01 2003-07-30 Praecis Pharmaceuticals Incorporated Peptides as met-ap2 inhibitors
US6548477B1 (en) 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
ES2329553T4 (es) 2000-12-20 2010-12-07 Bristol-Myers Squibb Company Pirroloquinolinas y piridoquinolinas sustituidas como agonistas y antagonistas de serotonina.
US20040116495A1 (en) 2001-03-29 2004-06-17 Marino Jr. Joseph P. Compounds and methods
US20020183242A1 (en) 2001-04-11 2002-12-05 Jack Henkin Peptide antiangiogenic drugs
DE60233420D1 (de) 2001-09-27 2009-10-01 Equispharm Co Ltd Fumagillolderivate und verfahren zu deren herstellung
US6803382B2 (en) 2001-11-09 2004-10-12 Galderma Research & Development, S.N.C. Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof
US7119120B2 (en) 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
KR100451485B1 (ko) 2002-03-28 2004-10-06 주식회사종근당 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
US6989392B2 (en) 2002-06-18 2006-01-24 Abbott Laboratories 2-Aminoquinolines as melanin concentrating hormone receptor antagonists
US7030262B2 (en) 2002-08-06 2006-04-18 Abbott Laboratories 3-Amino-2-hydroxyalkanoic acids and their prodrugs
US20040067266A1 (en) 2002-10-07 2004-04-08 Toppo Frank R. Weight loss compound
US20040068012A1 (en) 2002-10-08 2004-04-08 Comess Kenneth M. Sulfonamides having antiangiogenic and anticancer activity
US20040157836A1 (en) 2002-10-08 2004-08-12 Comess Kenneth M. Sulfonamides having antiangiogenic and anticancer activity
US7491718B2 (en) 2002-10-08 2009-02-17 Abbott Laboratories Sulfonamides having antiangiogenic and anticancer activity
US20040204472A1 (en) 2003-03-04 2004-10-14 Pharmacia Corporation Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
ATE403650T1 (de) 2003-08-08 2008-08-15 Janssen Pharmaceutica Nv 2- (chinoxalin-5-ylsulfonylamino) - benzamidverbindungen als cck2-modulatoren
AR046330A1 (es) 2003-09-09 2005-12-07 Japan Tobacco Inc Inhibidor de dipeptidilpeptidasa iv
CA2550689A1 (en) 2003-12-22 2005-07-14 Memory Pharmaceuticals Corporation Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
JP2007537147A (ja) 2003-12-29 2007-12-20 プレーシス ファーマスーティカルズ インコーポレイテッド メチオニンアミノペプチダーゼ−２のインヒビターおよびその使用
KR100552043B1 (ko) 2004-02-28 2006-02-20 주식회사종근당 푸마질롤 유도체를 포함하는 비만치료용 조성물
WO2005113513A2 (en) 2004-05-12 2005-12-01 Chemocentryx Aryl sulfonamides
JP2008505176A (ja) 2004-06-30 2008-02-21 コンビナトアールエックス インコーポレーティッド 代謝障害を治療するための方法および試薬
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
AU2005289887A1 (en) 2004-09-24 2006-04-06 Janssen Pharmaceutica, N.V. Sulfonamide compounds
WO2006080591A1 (en) 2005-01-26 2006-08-03 Chong Kun Dang Pharmaceutical Corp. Fumagillol derivatives or method for preparation of fumagillol derivatives, and pharmaceutical compositions comprising the same
FR2886855B1 (fr) 2005-06-08 2009-07-17 Agronomique Inst Nat Rech Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
US20070078172A1 (en) 2005-06-16 2007-04-05 Jenrin Discovery Mao-b inhibitors useful for treating obesity
AU2006330587B2 (en) 2005-12-23 2012-12-13 Glaxosmithkline Llc Azaindole inhibitors of aurora kinases
WO2008008374A2 (en) 2006-07-14 2008-01-17 Chemocentryx, Inc. Ccr2 inhibitors and methods of use thereof
DE102007020492A1 (de) 2007-04-30 2008-11-06 Grünenthal GmbH Substituierte Sulfonamid-Derivate
AU2008268262C1 (en) 2007-06-26 2015-02-19 Children's Medical Center Corporation MetAP-2 inhibitor polymersomes for therapeutic administration
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
EA020251B1 (ru) 2007-11-28 2014-09-30 Мерсана Терапьютикс, Инк. Биосовместимые и биоразлагаемые конъюгаты аналогов фумагиллина
DE502008003324D1 (de) 2007-11-30 2011-06-01 Bayer Schering Pharma Ag Heteroaryl-substituierte piperidine
CA2731020A1 (en) 2008-07-18 2010-01-21 Zafgen, Inc. Use of antiangiogenic fumagillins in the treatment of obesity
ES2641471T3 (es) 2008-10-06 2017-11-10 The Johns Hopkins University Compuestos de quinolina como inhibidores de la angiogénesis, metionina aminopeptidasa humana, y SirT1, y procedimientos de tratamiento de trastornos
US8906896B2 (en) 2008-10-24 2014-12-09 Ulrich Bierbach Platinum acridine anti-cancer compounds and methods thereof
US20120004162A1 (en) 2008-12-04 2012-01-05 Vath James E Methods of Treating an Overweight or Obese Subject
US20120010290A1 (en) 2008-12-04 2012-01-12 Vath James E Methods of Treating an Overweight or Obese Subject
US20120010259A1 (en) 2008-12-04 2012-01-12 Vath James E Methods of Treating an Overweight or Obese Subject
WO2010065883A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Method of treating an overweight or obese subject
AU2010303270A1 (en) 2009-10-09 2012-05-03 Zafgen Corporation Sulphone compounds for use in the treatment of obesity
US8815309B2 (en) 2010-01-08 2014-08-26 Zafgen, Inc. Methods of treating a subject with benign prostate hyperplasia
US20130023513A1 (en) 2010-01-12 2013-01-24 Hughes Thomas E Methods and Compositions for Treating Cardiovascular Disorders
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
US20130210821A1 (en) 2010-05-27 2013-08-15 James E. Vath Methods for Treating Obesity
US20120020647A1 (en) 2010-07-21 2012-01-26 Rovi Technologies Corporation Filtering repeated content
BR112013001613A2 (pt) * 2010-07-22 2016-05-24 Zafgen Inc compostos tricíclicos e métodos para fazer e usar os mesmos.
US8428080B2 (en) 2010-09-16 2013-04-23 Apple Inc. Method to control reconfiguration of multiple radio access bearers in a wireless device
US9221787B2 (en) 2010-10-12 2015-12-29 Zafgen, Inc. Sulphonamine compounds and methods of making and using same
UA111479C2 (uk) 2010-11-09 2016-05-10 Зафджен, Інк. Кристалічні форми інгібітору metap-2 та способи їх отримання і застосування
WO2012064928A1 (en) 2010-11-10 2012-05-18 Zafgen Corporation Methods and compositions for treating thyroid hormone related disorders
JP2013543899A (ja) 2010-11-29 2013-12-09 ザフゲン，インコーポレイテッド ６−ｏ−（４−ジメチルアミノエトキシ）シンナモイルフマギロールの非連日投与を用いた肥満の治療
WO2012074968A1 (en) 2010-11-29 2012-06-07 Zafgen Corporation Methods of reducing risk of hepatobiliary dysfunction during rapid weight loss with metap-2 inhibitors
WO2012075026A1 (en) 2010-11-29 2012-06-07 Zafgen Corporation Methods of treating obesity using an effective dose of a metap-2 inhibitor
CA2825408A1 (en) 2011-01-26 2012-08-02 Zafgen, Inc. Tetrazole compounds and methods of making and using same
WO2012154679A1 (en) 2011-05-06 2012-11-15 Zafgen Corporation Tricyclic pyrazole sulfonamide compounds and methods of making and using same
AU2012253757B2 (en) 2011-05-06 2017-04-13 Zafgen Inc. Partially saturated tricyclic compounds and methods of making and using same
EP2705036B1 (en) 2011-05-06 2015-08-12 Zafgen Inc. Tricyclic sulfonamide compounds and methods of making and using same
WO2013033430A1 (en) 2011-09-02 2013-03-07 Wake Forest School Of Medicine Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof
JP6035347B2 (ja) 2012-01-18 2016-11-30 ザフゲン，インコーポレイテッド 三環式スルホンアミド化合物ならびにその作製および使用方法
CA2861381A1 (en) 2012-01-18 2013-07-25 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
US10174009B2 (en) 2012-11-05 2019-01-08 Zafgen, Inc. Tricyclic sulphonamide compounds and methods of making and using same
KR20150080614A (ko) 2012-11-05 2015-07-09 자프겐 인크. 비만의 치료 및/또는 제어에서 사용하기 위한 트리시클릭 화합물
BR112015010196A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc métodos de tratar doença do fígado

Also Published As

Publication number Publication date
EP2917197A1 (en) 2015-09-16
CN104870433A (zh) 2015-08-26
KR20150079952A (ko) 2015-07-08
US20150284369A1 (en) 2015-10-08
BR112015010225A2 (pt) 2017-07-11
EP2917197B1 (en) 2019-06-05
US10174009B2 (en) 2019-01-08
CA2890342A1 (en) 2014-05-08
WO2014071363A1 (en) 2014-05-08
JP2015536981A (ja) 2015-12-24
AU2013337282A1 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
MX343687B (es) Compuestos sulfonamida tricíclica y métodos para su fabricación y uso.
MX345535B (es) Compuestos tricíclicos parcialmente saturados y métodos para su fabricación y su uso.
MX2014008705A (es) Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.
MX343688B (es) Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso.
MX2014008706A (es) Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
MX339201B (es) Compuestos de sulfonamida y métodos para elaborarlos y usarlos.
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
TN2015000278A1 (en) Autotaxin inhibitors
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
BR112013001613A2 (pt) compostos tricíclicos e métodos para fazer e usar os mesmos.
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
GB201209613D0 (en) New compounds
GB201118656D0 (en) New compounds
MX366899B (es) Nuevos compuestos.
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
MX2015005732A (es) Compuestos tricíclicos y métodos para hacer y utilizar los mismos.
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
MX2013002118A (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
MX2015005734A (es) Metodos de tratamiento de enfermedades hepaticas.